Missing Script · Evidence review
Fatigue can disappear inside the word “expected.” Expected during treatment. Expected after treatment. Expected to take time.
That may explain why someone feels exhausted. It does not tell them what might help. I want Missing Script to make more room for that second conversation, including options that need a careful reading of the evidence.
What the trial actually found
In the N07C2 randomized, double-blind trial, 364 participants received American ginseng or placebo for eight weeks. The studied preparation was Wisconsin American ginseng, Panax quinquefolius, at 2,000 mg daily.
The primary four-week fatigue comparison did not reach statistical significance: P=.07. At eight weeks, improvement on the fatigue scale was greater with ginseng, 20 points versus 10.3 with placebo, P=.003. People receiving active treatment appeared to benefit more than those who had completed it.
Reported toxicities did not differ significantly between groups. That is reassuring within this study; it does not establish safety for every combination of medications or every commercial preparation.
Where does it fit in guidance?
The 2024 ASCO–Society for Integrative Oncology fatigue guideline says American ginseng may be recommended during cancer treatment. The same guideline recommends exercise, cognitive behavioral therapy and mindfulness-based programs for fatigue during treatment.
I read that as an invitation to discuss an option in context. “May be recommended” leaves room for patient circumstances, clinical judgment and uncertainty. It is different from saying everyone with fatigue should take a supplement.
The label is part of the evidence
American ginseng, Asian ginseng and a bottle with “energy” on the front are not interchangeable evidence categories. The trial tested a particular species and preparation.
If someone brings a supplement to the clinic, I want to see the actual label. What is in it? What else has been added? How does that relate to the preparation in the paper? The dose above describes the research; it is not a personal dosing recommendation.
Keep the conversation broader than one bottle
My editorial starting point is to make fatigue itself visible. When does it happen? What activities have become difficult? What has already been tried? What would a meaningful improvement look like for this person?
Those questions help us avoid collecting interventions without a way to judge whether any of them are helping. They also make room for the clinical assessment and supportive-care options that should accompany a supplement discussion.
For the next visit, useful questions include: “Does the American ginseng evidence apply to my treatment setting?” “Can we review this exact preparation with my medications?” and “How would we track benefit and decide whether to continue?”
I think this evidence deserves a place in the conversation. Its limitations deserve the same attention.
Educational discussion. Review personal treatment and supplement decisions with your oncology team. Explore the article library → · Podcast: coming soon →
